# Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

Study · id `cardio:ct-nct07564726` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07564726](<https://clinicaltrials.gov/study/NCT07564726>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07564726

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

## Technical summary

Registry record NCT07564726. Randomized; quadruple masking; primary purpose treatment. Start 2022-08-05 (actual); primary completion 2024-02-13 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 163 participants (enrolled count; ClinicalTrials.gov record NCT07564726, source copy `cardio:ctgov-nct07564726-2026-05-08`, retrieved 2026-10-26)
- Started: 2022-08-05 (actual) (ClinicalTrials.gov record NCT07564726, source copy `cardio:ctgov-nct07564726-2026-05-08`, retrieved 2026-10-26)
- Primary completion: 2024-02-13 (actual) (ClinicalTrials.gov record NCT07564726, source copy `cardio:ctgov-nct07564726-2026-05-08`, retrieved 2026-10-26)
- Completion: 2024-02-13 (actual) (ClinicalTrials.gov record NCT07564726, source copy `cardio:ctgov-nct07564726-2026-05-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07564726, source copy `cardio:ctgov-nct07564726-2026-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07564726-2026-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol
- Condition: Hypertension
- Condition: Hypercholesterolemia
- Intervention (Drug): Amlodipine
- Intervention (Drug): Ezetimibe/Rosuvastatin
- Intervention (Drug): Ezetimibe/Rosuvastatin Placebo
- Intervention (Drug): Amlodipine Placebo
- Lead sponsor: Celltrion Pharm, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Amlodipine (`cardio:amlodipine`)

## Provenance

Content hash: faf9fa73d4241a938ae4b5e705f56680cb6dc6c16e2b90da8c502cf56fecfe0f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
